Blueprint Medicines holds the No. 55 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics ( ADMA ), Catalyst Pharmaceuticals ( CPRX ) and Exelixis ( EXEL ) are among the top 5 highly rated stocks within the group.